Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a functional long non-coding RNA involved in many biologic processes. The study was aimed to explore the functional roles of MALAT1 in osteosarcoma progression.
Background
Osteosarcoma is a rare primary malignant bone tumor, particularly among children and adolescents [1] [2] [3] . Surgical removal combined with systemic multidrug chemotherapy is the most frequent approaches for osteosarcoma treatment. This strategy includes neoadjuvant chemotherapy followed by surgical removal of the primary tumor, along with the addition of adjuvant chemotherapy after surgery. With the introduction of neoadjuvant chemotherapy (including doxorubicin, cisplatin, methotrexate, ifosfamide and etoposide), long-term overall survival of osteosarcoma patients has dramatically improved to 65% to 70% [4] . However, patients with metastases have a poor prognosis, with overall survival of 10% to 30% [5] . Therefore, understanding of the molecular mechanisms underlying osteosarcoma metastasis may provide novel insights and help develop targeted therapeutic strategies.
Long non-coding RNAs (lncRNAs) are non-protein-coding transcripts that are longer than 200 nucleotides [6] . Emerging evidence demonstrated that lncRNAs not only play critical regulatory roles in tumorigenesis and tumor progression, but also serve as independent predictors for patient prognosis [7, 8] . For example, non-small cell lung cancer patients with high lncRNA SNHG1 expression were significantly correlated with poor overall survival, and further analysis revealed lncRNA SNHG1 could promote cell proliferation via miR-101-3p/SOX9/ Wnt/b-catenin axis [9] .
Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a highly conserved and frequently upregulated lncRNA in mammals. Recently, MALAT1 has been reported to have important molecular functional during cancer progression in several human cancers [10, 11] . High level of MALAT1 was associated with poor prognosis in oral squamous cell carcinoma and MALAT1 promoted cell migration and invasion through activation of b-catenin and NF-kB signaling pathways [12] . MALAT1 silencing suppressed human hematoma cell growth and metastasis via sponging miR-195 [13] . However, the functional role of MALAT1 in the carcinogenesis and tumor development of osteosarcoma remains unclear.
The c-Met proto-oncogene encodes the tyrosine kinase receptor of hepatocyte growth factor (HGF). Previous studies indicated that HGF/c-Met regulate cell migration and invasion in osteosarcoma [14] [15] [16] [17] . SOX4 (SRY (sex determining region Y)-box 4) is a downstream target gene of TGF-b and WNT/b-catenin pathway, and has been reported to be a key regulator of epithelialmesenchymal transition (EMT) and cancer metastasis [18] [19] [20] [21] . However, a more detailed role of c-Met in the promotion cell metastasis in osteosarcoma has not been elucidated.
In the present study, we confirmed that MALAT1 were highly expressed in osteosarcoma tissues and cell lines. Knockdown of MALAT1 dramatically suppressed cell proliferation and metastasis. We also demonstrated that MALAT1 was a direct target of miR-34a/c-5p and miR-449a/b, and upregulated MALAT1 functions as a competing endogenous RNAs (ceRNA) of c-Met and SOX4. Taken together, this study provided a novel insight of MALAT1 in control of osteosarcoma metastasis.
Material and Methods

Cell culture and tissue samples
Human osteosarcoma cell lines (MNNG/HOS, Saos-2, U2OS, and MG-63) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Human osteoblast cell line hFOB 1.19 was purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). All cells were maintained at 37°C in a humidified 5% CO 2 atmosphere. A total of 76 osteosarcoma tissues and paired adjacent non-tumor tissues from surgical resection were collected at the First Affiliated Hospital, College of Medicine, Zhejiang University during January 2011 and December 2015. The clinical features of enrolled osteosarcoma patients are shown in 
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Plasmid construction, siRNA and miRNA transfection
Fragments of the 3' untranslated regions (3'UTRs) of c-Met, SOX4, and MALAT1 containing the predicted miR-34a/c-5p and miR-449a/b binding sites were cloned and inserted into the pmirGLO dual-luciferase miRNA target expression vector at the SacI and XbaI restriction sites. miR-34a/c-5p and miR449a/b mimics/inhibitors, miRNA negative control, c-Met, MALAT1 and SOX4 siRNA and siRNA control were synthesized by GenePharma Company (Shanghai, China). Transfection was performed using HiPerFect Transfection Reagent (Qiagen, Hilden, Germany) according to the manufacturer's protocol.
RNA isolation and quantitative real-time PCR (qRT-PCR)
Total RNA from tissues and cell lines was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The gene expression was determined using SYBR Green PCR master mix (Applied Biosystems) and b-actin was used as an endogenous control. For miRNAs, qRT-PCR was carried out using Taqman miRNA Assays (Applied Biosystems, Foster City, CA, USA) and normalized to U6.
Dual-luciferase reporter assay
For luciferase assay, cells were plated in 24-well culture plates, and then co-transfected with pmirGLO-MALAT1-WT, pmirGLOc-Met-WT, pmirGLO-SOX4-WT or -MUT reporter plasmids and miR-34a/c-5p or miR-449a/b mimic or negative control. Then, the cells were harvested and lysed for luciferase assay 24 hours after transfection. Luciferase activity was detected using the Dual Luciferase Reporter Assay System (Promega). Renilla luciferase was used for normalization.
Cell counting kit-8 (CCK-8) assay
After 24 hours of transfection, 4×10 3 cells/well were seeded in 96-well plates and then cultured for different time (24 hours, 48 hours, 72 hours, and 96 hours). Cell viability was assessed using the CCK-8 assay according to the manufacturer's instructions. The optical density was measured at 450 nm using a spectrophotometer.
Cell migration and invasion assay
For migration assay, cells were incubated in serum-free medium for 48 hours after being scratched with a pipette tip. For the invasion assay, cells were seeded on the Matrigel-coated upper chamber (Corning Costar, Rochester, NY, USA) in serumfree medium. Complete medium containing 10% FBS was added to the lower chamber. After 24 hours incubation, cells were fixed in methanol and stained with 0.1% crystal violet for visualization.
Western blot analysis
Total protein lysates were prepared in RIPA lysis buffer and separated on 10% SDS-PAGE gel. Primary antibodies used in this study were as follows: rabbit mAb anti-c-Met (CST, #8198), mouse mAb anti-SOX4 (Santa Cruz, sc-130633) and rabbit mAb anti-b-actin (CST, #4970) were used for western blot analysis. Relative proteins expression levels were normalized to b-actin levels.
Statistical analysis
Each experiment was performed at least 3 times. Data was expressed as means ±SD. Statistical analysis were performed by Student's t-test using SPSS18.0 software. P value <0.05 was considered statistically significant.
Results
MALAT1 was frequently upregulated and associated with poor overall survival in osteosarcoma patients
We first determined the expression of MALAT1 in 76 osteosarcoma tissues and paired adjacent non-tumor tissues using qRT-PCR. An obviously upregulated expression of MALAT1 was observed in osteosarcoma tissues compared with adjacent non-tumor tissues ( Figure 1A ; P<0.01). Similarly, expression of MALAT1 was increased in all 4 human osteosarcoma cell lines compared with normal osteoblastic cells ( Figure 1B ; P<0.01). We also determined the association between MALAT1 expression and osteosarcoma metastasis and found that MALAT1 level in metastatic osteosarcoma tissues was significantly increased compared with locoregional osteosarcoma tissues ( Figure 1C ; P<0.01). When correlated to disease outcome, high expression of MALAT1 in osteosarcoma patients was significantly associated with worse prognosis ( Figure 1D ; P=0.011). These results suggest that MALAT1 may function as a potential oncogene involved in osteosarcoma metastasis.
Silence of MALAT1 suppressed proliferation, migration, and invasion of osteosarcoma cells
To determine the biological function of MALAT1 in osteosarcoma, siRNA against MALAT1 was transfected into MG63 cells and qRT-PCR was performed to confirm successful acquisition of MALAT1 silence ( 
Silence of MALAT1 suppressed c-Met and SOX4 expression
Abnormal expressions of c-Met and SOX4 have been correlated with tumorigenesis and tumor progression through the induction of an epithelial-to-mesenchymal transition and metastasis [22] . To investigate whether MALAT1 exert its regulatory effect through c-Met or SOX4, MALAT1 siRNA was transfected into MG-63 cells. As shown in Figure 3A and 3B, silence of MALAT1 reduced the expression of c-Met and SOX4 at both the mRNA and protein levels in MG-63 cells. To further explore the relationship between MALAT1 and these 2 genes, we determined the mRNA level in human osteosarcoma tissues using qRT-PCR. As shown in Figure 3C and 3D, c-Met and SOX4 mRNA levels in osteosarcoma tissues were significantly higher than that of adjacent non-tumor tissues. MALAT1 transcript level was obviously correlated with c-Met and SOX4 mRNA transcript levels. Person correlation analysis showed a significant positive correlation between MALAT1 level and c-Met or SOX4 mRNA expression in osteosarcoma tissues (Figure 3E, 3F ; R=0.6182, P<0.0001; R=0.5854, P<0.0001, respectively).
miR-34a/c-5p and miR-449a/b were predicted to be candidate miRNAs Accumulated evidence suggests lncRNAs could regulate their target genes by acting as either ceRNAs for microRNAs (miRNAs) or as miRNA sponges [23] [24] [25] . To explore whether Figure 4A ). Among the miRNAs, miR-34a, miR-34c-5p, miR-449a, and miR-449b were identified as candidate miRNAs which were further confirmed to be downregulated in osteosarcoma cell lines compared with normal bones using Gene Expression Omnibus (GEO) dataset GSE28423 (Table 2 ) [28] .
The qRT-PCR results showed the expression of miR-34a, miR34c-5p, miR-449a, and miR-449b in osteosarcoma tissues were decreased 1.65-fold, 2.04-fold, 3.16-fold, and 2.75-fold compared with normal tissues, respectively ( Figure 4B-4E ). These findings suggest that MALAT1 may serve as a ceRNA for miR34a/c-5p and miR-449a/b. 
MALAT1 functioned as a ceRNA of c-Met and SOX4 by directly binding to miR-34a/c-5p and miR-449a/b
The predicted binding sites for miR-34a/c-5p and miR-449a/b in c-Met, SOX4, and MALAT1 are shown in Figure 5A . c-Met 3'UTR has 2 binding sites at position 51-57 and 2165-2171. SOX4 3'UTR and MALAT1 have 1 binding site at 2575-2581 and 3206-3212, respectively. To verify these predicted relationships, dual-luciferase reporter assay were employed and the results showed the luciferase activity of the wild type (WT) of MALAT1, c-Met 3'UTR,and SOX4 3'UTR reporter vectors, but not mutant (Mut) vectors, was significantly reduced after transfected with hsa-miR-34a, hsa-miR-34c-5p, hsa-miR-449a, or hsa-miR-449b mimics compared with miRNA negative control ( Figure 5B ). Knockdown of MALAT1 in MG-63 cells could significantly reduce c-Met expression in both mRNA and protein levels. However, co-transfection with MALAT1 siRNA and miRNA inhibitors (miR-34a/c-5p and miR-449a/b) obviously increased c-Met expression compared with that of MALAT1 siRNA alone or MALAT1 siRNA with miRNA negative control ( Figure 5C ). Table 2 . Expression levels of miR-34a/c-5p and miR-449a/b in GEO dataset GSE28423. MALAT1 required miR-34a/c-5p or miR-449a/b to promote proliferation and metastasis of osteosarcoma cells
Predicted binding sites Position
Next, we evaluated the influence of miR-34a/c-5p or miR449a/b on the proliferation and metastasis of osteosarcoma cells induced by MALAT1. MALAT1 siRNA and miR-34a/c-5p or miR-449a/b inhibitors were co-transfected into MG-63 cells. CCK-8 assay showed that the inhibition of MALAT1 siRNA to cell proliferation could be obviously removed by co-transfected with miRNA inhibitors compared with miRNA negative control ( Figure 6A ). Transwell migration and invasion assays also demonstrated that miR-34a/c-5p or miR-449a/b could partly eliminate the effects of MALAT1 on migration and invasion of MG-63 cells ( Figure 6B, 6C) . These results suggest essential roles of miR-34a/c-5p and miR-449a/b in the regulation of MALAT1-mediated osteosarcoma cell proliferation and metastasis ( Figure 6D ).
Discussion
Metastasis is the primary cause of mortality associated with cancer. Although metastasis only occurs to approximately 15% to 20% of osteosarcoma patients, 10% to 30% of long-term survival rates is extremely low compared with 65% and 70% in non-metastasis patients [29, 30] . In this study, we demonstrated that MALAT1 is an oncogene associated with cell proliferation and metastasis in osteosarcoma, consistent with recent studies [31] [32] [33] [34] . Except for proliferation and metastasis, MALAT1 was also reported to play an important role in cell differentiation, chemoresistance, and inflammatory response [35] [36] [37] . These findings inspired us to explore the underlying mechanism of MALAT1 regulating osteosarcoma cell metastasis.
It is believed that c-Met and SOX4 are important metastasis related genes which contribute to proliferation and metastasis in a variety of human malignancies. We further investigated whether MALAT1 promoting cell proliferation and metastasis is via regulating c-Met and SOX4. Knockdown of MALAT1 in MG-63 cells significantly reduced c-Met and SOX4 expression. Clinical data further showed a positive correlation between MALAT1 and c-Met or SOX4 expression. These results indicate MALAT1 might exert its functions through regulating c-Met and SOX4 in osteosarcoma.
The ceRNA hypothesis provides us a novel direction to understand lncRNA-miRNA-mRNA interaction in regulation of tumorigenesis and progression in human cancers [37, 38] . In this study, we identified 4 candidate miRNAs: miR-34a, miR-34c-5p, miR-449a, and miR-449b using online tool and GEO dataset.
Luciferase reporter assays showed a direct interaction between miR-34a, miR-34c-5p, miR-449a, or miR-449b and MALAT1, c-Met, or SOX4, respectively. When silence of those 4 miRNAs, MALAT1, c-Met, and SOX4 expression were increased compared with that of MALAT1 siRNA alone or MALAT1 siRNA with miRNA negative control. These findings indicate that MALAT1 could effectively regulate c-Met and SOX4 expression by competitively binding to miR-34a/c-5p and miR-449a/b.
MiR-34, a markedly conserved miRNA, has been regarded as a tumor suppressor in multiple cancers, including ovarian cancer, gastric cancer, and lung adenocarcinoma [39] [40] [41] . Bou Kheir et al. reported that downregulated miR-449 inhibits cell proliferation through regulation of a cohort of cancerassociated cell cycle regulators in gastric cancer [42] . Recently, several studies also suggest miR-34/449 family are essential for multi-ciliogenesis, spermatogenesis, motile ciliogenesis and normal brain development [43] [44] [45] . Our results showed miR-34a/c-5p and miR-449a/b were significantly downregulated and could partly eliminate the influences of MLAT1-induced proliferation and metastasis of osteosarcoma cells. Thus, miR-34 and miR-449 may also function as a tumor suppressor in osteosarcoma, and further studies are warranted to clarify the specific roles and underlying mechanisms of miR-34 and miR-449 in the development of osteosarcoma.
Conclusions
Our findings reveal a crucial role of MALAT1 and 2 miRNA clusters, miR-34a/c-5p and miR-449a/b in cell proliferation and metastasis of osteosarcoma. Our work also establishes a novel ceRNA interaction network and understanding such mechanisms may eventually lead to novel therapeutic strategies based on non-coding RNA for osteosarcoma patients.
